Keyphrases
Epidemiology
100%
Carbapenem-resistant Enterobacteriaceae
67%
Risk Factors
67%
Extended-spectrum-lactamase
62%
Bloodstream Infection
59%
Medical Center
51%
Multidrug-resistant Organisms
50%
Odds Ratio
48%
Vancomycin-resistant Enterococci
44%
Acinetobacter Baumannii (A. baumannii)
40%
Detroit
40%
Colistin
36%
Enterobacteriaceae
35%
Carbapenems
35%
Older Adults
35%
Confidence Interval
35%
Carbapenem Resistance
34%
Clinical Outcomes
33%
Baumannii
33%
Bacteremia
32%
Antimicrobial Resistance
32%
Case-case
31%
Multidrug-resistant
30%
Antimicrobial
29%
Israel
27%
Klebsiella Pneumoniae (K. pneumoniae)
25%
Group B Streptococcus
25%
Prudent Antimicrobial Use
24%
Escherichia Coli
21%
Molecular Epidemiology
21%
Acute Hospital
20%
Pseudomonas Aeruginosa (P. aeruginosa)
19%
Human Pathogens
19%
Michigan
19%
Israeli
17%
Iatrogenic Complications
17%
Risk Outcomes
17%
Producing Escherichia Coli
16%
Carbapenem-resistant Acinetobacter Baumannii
16%
Southern Israel
16%
Match Analysis
16%
Enterobacter
16%
Sequence Type
16%
Low Incidence
16%
Neonatal Disease
15%
Daptomycin
15%
Medical Care
15%
Antimicrobial Therapy
15%
Multidrug-resistant Gram-negative Bacteria
14%
Methicillin-resistant Staphylococcus Aureus
14%
Medicine and Dentistry
Infection
83%
Cohort Effect
72%
Carbapenem-Resistant Enterobacteriaceae
62%
Bloodstream Infection
57%
Penicillinase
50%
Carbapenem
42%
Pathogen
40%
Antiinfective Agent
37%
Odds Ratio
34%
Emergency Care
32%
Extended Spectrum Beta Lactamase
30%
Enterobacteriaceae
28%
Streptococcus Agalactiae
25%
Acinetobacter Baumannii
22%
Gram-Negative Bacteria
21%
Pseudomonas aeruginosa
21%
Molecular Epidemiology
20%
Carbapenem Derivative
18%
Escherichia coli
18%
Sepsis
18%
Newborn Disease
17%
Prevalence
15%
Colistimethate
15%
Antibiotic Resistance
15%
Infection Control
14%
Pathogenesis
14%
Enterobacteriaceae Infection
14%
Klebsiella pneumoniae
13%
Antimicrobial Therapy
12%
Hospital Infection
12%
Logistic Regression Analysis
12%
Acinetobacter Infection
12%
Infection Prevention
11%
Surgical Infection
11%
Vancomycin Resistant Enterococcus
11%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
10%
Iatrogenesis
10%
Cohort Analysis
10%
Multilocus Sequence Typing
9%
Health Care Cost
9%
Proportional Hazards Model
9%
Polymerase Chain Reaction
9%
Bacteremia
9%
Medical Care
9%
Disease
8%
Decubitus
8%
Healthcare Associated Infection
8%
Retrospective Cohort Study
7%
Serotype
7%
Mortality Rate
7%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
70%
Carbapenem Resistant Enterobacteriaceae
46%
Carbapenem
42%
Bloodstream Infection
41%
Penicillinase
38%
Vancomycin-Resistant Enterococcus
34%
Bacteremia
31%
Antiinfective Agent
31%
Extended Spectrum Beta Lactamase
31%
Infectious Agent
30%
Antimicrobial Therapy
28%
Enterococcus faecalis
23%
Enterobacteriaceae
22%
Colistimethate
21%
Pseudomonas aeruginosa
20%
Enterobacteriaceae Infection
19%
Vancomycin
18%
Enterobacter
17%
Acinetobacter Baumannii
15%
Case-Control Study
14%
Gram Negative Bacterium
14%
Linezolid
14%
Klebsiella pneumoniae
13%
Streptococcus Agalactiae
13%
Carbapenem Derivative
13%
Cephalosporin Derivative
11%
Tigecycline
11%
Urinary Tract Infection
11%
Newborn Disease
11%
Cohort Study
11%
Disease
10%
Prevalence
9%
Daptomycin
9%
Antimicrobial Resistance
9%
Beta Lactam
8%
Pathogenesis
8%
Beta Lactam Antibiotic
8%
Deterioration
8%
Quinolone Derivative
8%
Sepsis
7%
Hospital Mortality
7%
Multiple Drug Resistance
7%
Endocarditis
7%
Antibiotic Agent
7%
Imipenem
7%
Escherichia coli
7%
Carbapenem Resistance
6%
Hemodialysis
6%
Carbapenemase
6%
Cotrimoxazole
6%